首页> 美国卫生研究院文献>Springer Open Choice >Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies
【2h】

Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies

机译:肾素-血管紧张素系统抑制剂与骨折风险:前瞻性队列研究和已发表的观察性队列研究的荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The renin-angiotensin system (RAS) represents an important target of antihypertensive medications. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), which are widely-used RAS inhibiting drugs, have been suggested to have beneficial effects on bone tissue. We aimed to assess the associations of use of ACEIs and/or ARBs with the risk of fractures using a population-based prospective cohort and a meta-analysis of published prospective cohort studies. Information on antihypertensive medication use (including both ACEIs and ARBs) were assessed in 1743 men and women of the Kuopio Ischemic Heart Disease prospective cohort study. Hazard ratios (HRs) [95% confidence intervals (CI)] of ACEIs or ARBs use with incident fractures were calculated. A total of 203 composite (hip, humeral, and wrist) fractures occurred during a median follow-up of 14.8 years. In multivariate adjusted analysis, the HR for composite fractures comparing users of ACEIs or ARBs with non-users was 1.00 (0.59–1.69). The corresponding adjusted HR for hip fractures comparing users versus non-users of ACEIs or ARBs was 0.89 (0.32–2.47). Including the current study, a total of 11 observational cohort studies involving 3526,319 participants and >323,355 fractures were included in a meta-analysis. Comparing ACEI users with non-users and ARB users with non-users, the HRs for composite fractures were 1.09 (0.89–1.33) and 0.87 (0.76–1.01) respectively. The corresponding HRs for hip fractures were 0.91 (0.86–0.95) and 0.80 (0.75–0.85) respectively. Use of RAS inhibitors was not associated with long-term risk of composite fractures in both primary and pooled analyses. Pooled evidence however suggests a beneficial effect of RAS blockers on hip fracture risk.Electronic supplementary materialThe online version of this article (doi:10.1007/s10654-017-0285-4) contains supplementary material, which is available to authorized users.
机译:肾素-血管紧张素系统(RAS)代表降压药物的重要靶标。血管紧张素转换酶抑制剂(ACEI)和血管紧张素II受体阻滞剂(ARB)是广泛使用的RAS抑制药物,已被认为对骨骼组织具有有益作用。我们旨在通过基于人群的前瞻性队列研究和已发表的前瞻性队列研究的荟萃分析,评估ACEI和/或ARB的使用与骨折风险之间的关系。在1743名Kuopio缺血性心脏病前瞻性队列研究的男性和女性中,评估了使用降压药的信息(包括ACEI和ARB)。计算了事故性骨折使用的ACEI或ARB的危险比(HR)[95%置信区间(CI)]。在14.8年的中位随访期间共发生203例复合性(髋部,肱骨和腕部)骨折。在多变量校正分析中,将ACEIs或ARB使用者与非使用者进行比较的复合骨折的HR为1.00(0.59-1.69)。比较使用ACEI和未使用ACEI或ARB的髋部骨折的相应调整后HR为0.89(0.32–2.47)。包括本研究在内,荟萃分析共包括11项观察性队列研究,涉及3526319名参与者和> 323,355例骨折。将ACEI用户与非用户和ARB用户与非用户进行比较,复合骨折的HR分别为1.09(0.89–1.33)和0.87(0.76-1.01)。髋部骨折的相应心率分别为0.91(0.86-0.95)和0.80(0.75-0.85)。在主要分析和合并分析中,使用RAS抑制剂与复合材料骨折的长期风险均不相关。但是,汇总的证据表明RAS阻滞剂对髋部骨折风险具有有益作用。电子补充材料本文的在线版本(doi:10.1007 / s10654-017-0285-4)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号